Guardant Health Inc.今日盘前大涨5.49%,引发市场广泛关注。这很可能与公司刚刚公布的最新财报表现亮眼有关。
Guardant Health Inc.公布的最新季度业绩显示,公司营收同比增长30.2%至2.0181亿美元,超过分析师预期。尽管当季每股亏损90美分未达预期,但亏损金额较上季度有所收窄,显示公司盈利能力正在改善。
分析师普遍看好这家肿瘤液体活检公司的前景。目前22位分析师给予该股"买入"或"强烈买入"评级,12个月目标价中位数为47美元,较目前股价有较大上涨空间。公司强劲的营收增长以及亏损状况的持续改善,有望继续支撑其股价上涨动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.